Skip to main content
Caplight Logo









OMass Therapeutics

OMass Therapeutics

Private
OxfordHealthcare & Life Scienceshttps://www.omass.com/

Last Round

Series B

Extension

May 15, 2023

Est. Valuation

$498M

Total Funding Raised

$166.1M

Company Overview

OMass Therapeutics is a biotechnology company that discovers and develops novel small molecule medicines for rare diseases and immunological conditions using its proprietary structural mass spectrometry technology platform.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

small molecule drug discoverynative mass spectrometryprotein complexdrug discovery platformundruggable targetsbiotech partnershipinflammatory bowel diseaseIBDdrug developmentprotein interactionbiopharmadrug discovery pipelinepreclinical researchdrug licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

OMass Therapeutics Comparables

Compare OMass Therapeutics with similar companies based on industry and business-model similarity.

OMass Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Confo Therapeutics
79%
HotSpot Therapeutics
78%
Frontier Medicines
78%

OMass Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionMay 15, 2023
Series BApr 28, 2022
Series A ExtensionFeb 17, 2020
Series ANov 20, 2018

Key People

Founding team and executive leadership

Ros Deegan

CEO

Executive Team

OMass Therapeutics Investors

Notable investors and investment history

OMass Therapeutics investors
InvestorRounds
GVSeries B Extension, Series B
SynconaSeries B, Series B Extension, Series A Extension, Series A
Oxford Science EnterprisesSeries A Extension, Series B, Series B Extension, Series A
British Patient CapitalSeries B Extension
Northpond VenturesSeries B Extension, Series B
University of OxfordSeries A Extension, Series B
Sanofi VenturesSeries B Extension, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 28, 2026

    Company faces lawsuit over intellectual property dispute.

  • Jan 28, 2026

    Jonathan Montagu appointed as new Board Chair.

OMass Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

OMass Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about OMass Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range76
Year Founded2016
Last FundingMay 15, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?